LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

LLY

1,045.2

+0.07%↑

JNJ

246.17

+0.3%↑

ABBV

228.99

+0.04%↑

NVS

167.04

+1.08%↑

MRK

123.55

+1.05%↑

Home・Akcijų sąrašas・Vaxart Inc

Vaxart Inc

Atidarymo kaina

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	6.8M -8.1M
Pardavimai	33M 72M
Pelno marža	-11.242
Darbuotojai	105
EBITDA	6.7M -5.4M

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	45M 136M
Ankstesnė atidarymo kaina	0
Ankstesnė uždarymo kaina	0

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

0.4007 / 0.4252 Palaikymas ir pasipriešinimas

Vaxart Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-23 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

2026-02-23 22:36; UTC

Uždarbis

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

2026-02-23 22:32; UTC

Uždarbis

Woodside Energy Fiscal Year Net Profit Falls 24%

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

2026-02-23 23:58; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-23 23:47; UTC

Rinkos pokalbiai

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

2026-02-23 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

2026-02-23 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Crescent Capital Partners Owns 53% of ClearView Wealth

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

2026-02-23 23:40; UTC

Rinkos pokalbiai

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

2026-02-23 23:40; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

2026-02-23 23:39; UTC

Įsigijimai, susijungimai, perėmimai

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

2026-02-23 23:31; UTC

Uždarbis

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

2026-02-23 23:28; UTC

Uždarbis

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

2026-02-23 23:27; UTC

Uždarbis

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

2026-02-23 23:24; UTC

Rinkos pokalbiai

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

2026-02-23 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

2026-02-23 22:31; UTC

Uždarbis

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

2026-02-23 22:24; UTC

Uždarbis

Viva Energy Energy & Infrastructure Ebitda A$93 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy FY Underlying Ebitda A$700.9 Million

2026-02-23 22:22; UTC

Uždarbis

Viva Energy Final Dividend 3.94 Australian Cents/Security

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

2026-02-23 22:21; UTC

Uždarbis

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

2026-02-23 22:20; UTC

Uždarbis

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Akcijų palyginimas

Kainos pokytis

Vaxart Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Vaxart Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.4007 / 0.4252Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

There is one bearish event.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.